stronger quarter overal support share repurchas spinraza
headlin number miss despit larger structur issu biogen
print rel good revenu beat
ep beat ms good enough beat overal
like driven better patient number highlight spinraza miss
despit increas patient therapi global think
may patient mix commerci vs eap region like
ou patient believ miss driven
zolgensmaa like seen later year fd share
count also lower expect vs acceler buy
back amount quarter call expect
commentari ms busi driver surpris growth posit
sma franchis zolgensma approv risdiplam file
detail evolv busi strategi print slightli
stronger expect larger structur issu remain
repurchas support share near-term howev absent
reiter under-perform pt
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater expect rate new therapi take greater
expect share near-term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
cog revenu
 revenu
sg revenu
actual con
revenu
non-gaap ep
non-gaap sg
non-gaap
non-gaap tax
charl martineau pm univers toronto compani mention price
